Biomarkers for immune checkpoint inhibitors in colorectal cancer:recent advances and future perspectives

查看全文 作　　者：Changjiang [1]Yang;Long [1]Zhao;Yilin [1]Lin;Shan [1]Wang;Yingjiang [1]Ye;Zhanlong [1]Shen

机构地区：[1]Department of Gastroenterological Surgery,Laboratory of Surgical Oncology,Key Laboratory of Colorectal Cancer Diagnosis and Treatment Research,Peking University People’s Hospital,Beijing 100044,China

出　　处：《Cancer Biology & Medicine》索引2023年第20卷第9期,共7页

基　　金：supported by the National Natural Science Foundation of China(Grant No.82272841). 摘　　要：Colorectal cancer(CRC)has become a major threat to human health.Recent years,improvements have been seen in the treatment of advanced CRC with immune checkpoint inhibitors(ICIs).Nonetheless,sensitivity to ICIs notably varies among patients,thus greatly limiting clinical applications of ICIs in CRC.Hence,the identification of biomarkers that can accurately distinguish between ICI-sensitive and drug-resistant patients is of utmost importance.Such biomarkers are essential for selecting appropriate treatment regimens and achieving precision therapy(Figure 1).The biomarkers discussed below provide insights into the advancements made in this field(Table 1). 关键词：cancer COLORECTAL FIGURE

相关文献

参考文献（34）
引证文献（2）
耦合文献（0）

参考文献(34)

引证文献(2)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Biomarkers for immune checkpoint inhibitors in colorectal cancer:recent advances and future perspectives

参考文献(34)

引证文献(2)

用户提示